[go: up one dir, main page]

AR110317A1 - Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas - Google Patents

Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas

Info

Publication number
AR110317A1
AR110317A1 ARP170103409A ARP170103409A AR110317A1 AR 110317 A1 AR110317 A1 AR 110317A1 AR P170103409 A ARP170103409 A AR P170103409A AR P170103409 A ARP170103409 A AR P170103409A AR 110317 A1 AR110317 A1 AR 110317A1
Authority
AR
Argentina
Prior art keywords
ascorbic acid
chagas disease
quinona
compounds
mixture
Prior art date
Application number
ARP170103409A
Other languages
English (en)
Inventor
Ximenes Valdecir Farias
Nakamura Celso Vataru
Vnia Cristina Desoti
Oliveira Silva Lautenschlager Sueli De
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of AR110317A1 publication Critical patent/AR110317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método de tratamiento, prevención o alivio de uno o varios síntomas de la enfermedad de Chagas en un sujeto, que comprende la administración al sujeto de (i) ácido ascórbico o un enantiómero simple, una mezcla de enantiómeros o una mezcla de diastereómeros de ellos; o una de sus sales, solvatos o hidratos farmacéuticamente aceptables; y (ii) un compuesto de quinona o un enantiómero simple, una mezcla de enantiómeros o una mezcla de diastereómeros de ellos o una de sus sales, solvatos, hidratos o profármacos farmacéuticamente aceptables.
ARP170103409A 2016-12-06 2017-12-05 Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas AR110317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430758P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
AR110317A1 true AR110317A1 (es) 2019-03-20

Family

ID=62491595

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103409A AR110317A1 (es) 2016-12-06 2017-12-05 Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas

Country Status (9)

Country Link
US (2) US11998523B2 (es)
AR (1) AR110317A1 (es)
CL (1) CL2019001529A1 (es)
CO (1) CO2019007158A2 (es)
CR (1) CR20190323A (es)
EC (1) ECSP19048402A (es)
MX (2) MX2019006593A (es)
PE (1) PE20191745A1 (es)
WO (1) WO2018106623A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US8507555B2 (en) 2006-06-16 2013-08-13 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) * 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) * 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
CN105232533A (zh) 2009-07-20 2016-01-13 萨马保健系统公司 维生素c和维生素k的组合及其用途
EP2595615A1 (en) 2010-07-19 2013-05-29 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
MX345788B (es) 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Nuevo tratamiento del carcinoma de prostata.
MX2020013076A (es) 2018-06-06 2021-03-02 Ic Medtech Corp Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria.

Also Published As

Publication number Publication date
US20240398755A1 (en) 2024-12-05
CR20190323A (es) 2019-11-11
WO2018106623A1 (en) 2018-06-14
BR112019011789A2 (pt) 2019-10-29
CL2019001529A1 (es) 2019-11-08
PE20191745A1 (es) 2019-12-12
US20190343794A1 (en) 2019-11-14
CO2019007158A2 (es) 2019-10-09
US11998523B2 (en) 2024-06-04
MX2022008055A (es) 2022-07-27
ECSP19048402A (es) 2019-09-30
MX2019006593A (es) 2019-09-13

Similar Documents

Publication Publication Date Title
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
SV2018005633A (es) Derivados de heteroarilo como inhibidores de parp
AR109452A1 (es) Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2018010191A (es) Inhibidores de glucosidasa.
EA201792116A1 (ru) Ингибитор янус-киназы
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
AR093705A1 (es) Depsipeptido y sus usos
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
SV2016005313A (es) Derivados de carboxamida
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
UY36123A (es) Derivados de carboxamida
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal